株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

癌・感染症の体外診断 (IVD) 検査開発事業者:トップ200社

The Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases

発行 Research Facts Ltd. 商品コード 452434
出版日 ページ情報 英文 360 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
癌・感染症の体外診断 (IVD) 検査開発事業者:トップ200社 The Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases
出版日: 2017年03月02日 ページ情報: 英文 360 Pages
概要

当レポートでは、癌・感染症の体外診断 (IVD) 検査の開発事業者トップ200社を調査し、企業情報、製品、臨床専門分野、収益などのデータをまとめています。

当企業プロファイルに含まれる情報

  • 企業名
  • 所在地
  • 電話番号
  • ファックス番号
  • Eメール
  • ウェブサイト
  • 設立年
  • 上級幹部
  • 企業概要
  • 製品
  • 臨床専門分野
  • 収益
  • ロケーション状況
  • オーナー構成
  • 証券コード
  • 親会社
目次

Did you know?

  • Lewis Stuart is Vice President, Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc..
  • Beijing Wantai Biological Pharmacy's Beijing plant is the largest manufacturing base for the production of infectious diseases diagnostics in China.
  • MDxHealth was the winner of the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award.
  • iTP Biomedica Corp., the Canadian developer of diagnostic tools for cancers, is oriented to collaborative co-diagnostics development.
  • Arbor Vita Corporation's flagship product - the OncoE6™ Cervical Test - has proven to be the most accurate test available worldwide for detecting cervical cancer. It is the only cervical cancer test that provides real-time results at the point-of-care.
  • On February 1, 2017, Great Basin Scientific, Inc. announced the completion of the clinical trial and 510(k) submission to the FDA of its Bordetella Direct Test.
  • Meridian Bioscience, Inc. reported full-year fiscal 2016 net revenues of $196.1 million.
  • In July, 2016, the Swiss-based global biopharmaceutical group, Debiopharm Group™, acquired a majority holding in GenePOC, Inc., the Canadian developer of affordable, simple, and rapid point-of-care molecular diagnostic tests for infectious diseases.

These are just a tiny sample of the 1,000's of facts to be found in 'The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases'.

This unique and comprehensive report (360 pages) identifies and profiles the leading 200 developers of in-vitro diagnostics tests for cancer and infectious diseases. They are located right across the globe from the United States and Europe to India and China.

Report Target Market:

1) In-Vitro Diagnostics Companies

Usage: competitive/financial analysis and strategic partner/alliance identification.

2) Suppliers

'The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases' is perfect for suppliers of raw materials, technology and services to identify top potential customers.

3) Distributors

This report is ideal for distributors of in-vitro diagnostics instruments and tests to identify the leading manufacturers with the best products.

4) Industry Associations:

'The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases' is a useful reference tool for in-vitro diagnostic associations.

Note: Most people will be aware of some of the major developers of in-vitro diagnostics tests for cancer and infectious diseases such as Accugenomics, Inc., Agendia Inc., altona Diagnostics GmbH, Biocept, Inc., bioLytical Laboratories Inc., GeneNews Limited, HiberGene Diagnostics and OvaGene Oncology, Inc. but this major new report looks at all 100 of the top companies - companies like:

GenMark Diagnostics, Inc. - Founded in 2010 and headquartered in Carlsbad, California, United States, GenMark Diagnostics, Inc. (NASDAQ: GNMK) is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimise patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. In June, 2016, the Company achieved the CE Mark for its ePlex® sample-to-answer multiplex molecular diagnostics System and ePlex® Respiratory Pathogen (RP) Panel and on December 22, 2016, GenMark announced that it had submitted 510(k) applications to the FDA for its ePlex® sample-to-answer System and Respiratory Pathogen (RP) Panel. The Company has revenue of $U.S. 49.2 million and 233 employees. GenMark is led by Hany Massarany, President And Chief Executive Officer.

Chembio Diagnostic Systems, Inc. - Headquartered in Medford, New York, United States, Chembio Diagnostic Systems, Inc. (Nasdaq: CEMI) develops, manufactures, licenses and markets point-of-care diagnostic tests and technology for the detection of infectious diseases. The Company's Dual Path Platform (DPP®) technology is providing it with a significant pipeline of business opportunities for the development and manufacture of new products. On January 10, 2017 Chembio Diagnostic Systems, Inc. announced that the Company had completed the acquisition of RVR Diagnostics Sdn Bhd (RVR), a Malaysian, privately-held manufacturer and distributor of point-of-care diagnostic tests for infectious diseases. Founded in 1985, Chembio Diagnostic Systems, Inc. had revenues of $U.S. 24.3 million in 2015. It currently has 166 employees and is led by John J. Sperzel, Chief Executive Officer.

Biocartis Group NV - Headquartered in Mechelen, Belgium, Biocartis Group NV is an innovative commercial stage, molecular diagnostics company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company's proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis Group NV is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases, the fastest and largest growing segments of the $U.S. 5.0 billion MDx market. The Company employs 300 people and has revenue of $U.S. 16.7 million. Biocartis Group NV has been listed on Euronext Brussels (BCART) since April 2015 and is led by Rudi Pauwels, Chief Executive Officer.

Research Facts is one of the world's leading companies in life sciences publishing. It has a large portfolio of best-selling reports spanning diagnostics, pharmaceuticals, biotechnology and medical devices. It's customers include most of the world's major companies in these sectors e.g. Abbott Laboratories, ACON Laboratories, Alcon, Allergan, Aurobindo Pharma, Axis-Shield, Baxter, Bayer, B. Braun, BD, Biomerieux, Biomet, Boehringer Ingelheim, CareFusion, Covance, Covidien, C.R. Bard, Edwards Lifesciences, Fresenius, GE Healthcare, Genzyme, HemoCue, Intuitive Surgical, Ipsen, Johnson & Johnson, Medtronic, Merit Medical Systems, Millipore, Mölnlycke Health Care, Novartis, Paul Hartmann, Philips Medical, Qiagen, Siemens Healthcare, Smith & Nephew, Synthes, Teleflex, Teva, Zentiva etc.. Research Facts also counts many multinational financial services, law and management consulting firms such as Bain & Company, McKinsey & Company and The Boston Consulting Group among its customers.

Research Facts currently has customers in some forty countries across the globe e.g. Austria, Australia, Belgium, Brazil, Canada, Cyprus, Czech Republic, Denmark, France, Germany, Finland, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Kuwait, Luxembourg, Mauritius, Netherlands, Pakistan, Peru, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, and the United States.

Research Facts' reports help you make informed decisions about the markets and organisations that affect your business.

  • Learn more about your target markets and target companies
  • Top level research on all the major players in a market
  • See which organisations dominate your major markets
  • Get detailed information on particular organisations
Back to Top